Sources | Names Used |
---|---|
CTRPv2 | doxorubicin:navitoclax (2:1 mol/mol) |
PharmacoGx | doxorubicin:navitoclax (2:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | OR4E2 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.001 |
mRNA | TK1 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.001 |
mRNA | TXNL4A | CTRPv2 | pan-cancer | AAC | 0.11 | 0.001 |
mRNA | LMNA | CTRPv2 | pan-cancer | AAC | -0.13 | 0.001 |
mRNA | NAIP | CTRPv2 | pan-cancer | AAC | 0.11 | 0.001 |
mRNA | NBPF19 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.001 |
mRNA | TAOK1 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.001 |
mRNA | WIF1 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.001 |
mRNA | FNDC9 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.001 |
mRNA | CXADR | CTRPv2 | pan-cancer | AAC | 0.12 | 0.001 |